ProLynx announces allowance of additional U.S. patent for PLX038, a novel DNA damage response enhancer
SAN FRANCISCO, April 10, 2018 (GLOBE NEWSWIRE) -- Prolynx LLC (San Francisco, CA) announced it received a Notice of Allowance for its DNA damage enhancer PLX038 (PEG~SN-38), currently in Phase 1 trials at MD Anderson. PLX038 is a prodrug of SN-38, the active metabolite of the anti-cancer agent Irinotecan, which inhibits Topoisomerase 1 (Topo 1) during DNA replication and causes replication stress and DNA damage. The new allowed claims expand ProLynx's broad patent coverage of PEG~SN-38 conjugates using ProLynx beta-eliminative linkers in US Patent 8,754,19.
DNA damaging agents, such as PLX038, have assumed a new importance in the context of the DNA damage response (DDR) and synthetic lethality. To combat threats posed by DNA damage, cells have mechanisms to signal the presence of DNA damage and promote its repair - collectively termed the DNA-damage response. Cells defective in DDR - as in many tumors - display heightened sensitivity towards DNA-damaging agents such as Topo 1 inhibitors. Such agents can increase DNA damage to a level that is tolerable to normal cells but lethal to cancer cells with DDR deficiencies. Hence, an effective Topo 1 inhibitor will enhance DNA damage and death of cells with DDR defects - such as cells deficient in DNA repair proteins BRCA, ATM or ATR - or in cells treated with inhibitors of DDR components - such as PARP, ATM or ATR inhibitors.
ProLynx's PLX038 slowly releases SN-38 such that tumors are exposed to the DNA-damaging agent SN-38 for long periods. In addition, the nanomolecule accumulates and remains in tumors for long periods, slowly releasing the drug at high intra-tumoral concentrations.
ProLynx's PEG~SN-38 conjugates show remarkable antitumor effects in mouse models of human tumors with DDR defects and those treated with DDR inhibitors. For example, in the BRCA1 human xenograft MX-1, a single, non-toxic dose completely inhibited tumor growth and resolved massive tumors. Likewise, a combination of low dose PEG~SN-38 with a PARP inhibitor completely inhibited tumor growth, and shrank large tumors. Moreover, a low dose of PEG~SN-38 followed by a period to allow tumor accumulation and systemic elimination sensitized the tumor such that treatment with a low dose of PARP inhibitor completely inhibited tumor growth.
Daniel Santi, cofounder and President of ProLynx, said, "PLX038 may provide a general agent for enhancing the selective killing of cancer cells with certain DDR defects. In addition, PLX038 seems to enhance the effects of other inhibitors that act on DDR components by synthetic lethality, suggesting that it may be used in combination with such agents."
About ProLynx: ProLynx LLC is a privately held biotechnology company located in San Francisco, CA, developing delivery systems for half-life extension of small molecules, peptides and proteins. The company applies its technology to extend half-lives of new drug candidates, and to improve properties of off-patent therapeutics. ProLynx has a monthly GLP-1 receptor agonist in its pre-clinical portfolio, and PLX038 in Phase 1 clinical trials. Further information about the company may be found at www.ProLynxllc.com.
Daniel.V.Santi@gmail.com 415-552-5306 or firstname.lastname@example.org 805-558-0361
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ProLynx LLC via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
HotDocs Wins Prestigious Queen's Award for Enterprise for International Trade26.4.2018 09:01 | Pressmeddelande
EDINBURGH, United Kingdom, April 26, 2018 (GLOBE NEWSWIRE) -- HotDocs, the global leader in document automation software powered by AbacusNext, has been named a winner of the 2018 Queen's Awards for Enterprise, the UK's highest accolade for business success. HotDocs received the award for achievement in International Trade in recognition of thriving overseas growth, accounting for an over seventy percent increase in revenue in the last three years. Since 1965, the Queen's Awards have recognised exceptional UK businesses who excel at international trade, innovations, or sustainable development-they are the highest official UK awards for enterprise excellence. HotDocs will be attending a reception at Buckingham Palace where Prince Charles will present the award on behalf of Her Majesty the Queen. This is HotDoc's second Queen's Award for Enterprise, the first was in 2013, also for excellence in International Trade. "We are proud to have been named a Queen's Award winner for the second ti
Historic GSA Meeting Forges Path for Blockchain Technology in Gaming Industry26.4.2018 09:00 | Pressmeddelande
LONDON, April 26, 2018 (GLOBE NEWSWIRE) -- The Gaming Standards Association's (GSA) recently formed Blockchain Technical Committee held its first meeting in London recently, charting a course to integrate the breakthrough technology into the gaming industry, with the potential to modernize lotteries and online and land-based gaming. The meeting was hosted by Playtech and attending were representatives from member companies, AxesNetwork, ComTrade Gaming, Gaming Laboratories International, Mercury Gaming Gauselmann, IGT, and Scientific Games. The topics of discussion included responsible gaming, machine certification, and jurisdictional licensing. "The spirit of collaboration among the members of this committee was groundbreaking, as everyone understands the mission critical responsibilities for the future of the global gaming industry," said Blockchain Committee Chair Earle G. Hall. "The enthusiasm and understanding of the task of the committee were infectious, and by the end of the day
SmartCash Highlights 2018 Initiatives to Accelerate Global Adoption, Recaps Key Achievements26.4.2018 09:00 | Pressmeddelande
Roadmap milestones focus on further scalability, merchant adoption, security and support NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- via NetworkWire -- SmartCash, a community governance, cooperation and growth focused crypto-asset created via blockchain technology, today provides an overview of its recent achievements and ambitions for the year ahead. Self-funded, Merchant-Centric, Community-Driven and Easy to Use Recent accomplishments have positioned SmartCash to become the ideal choice for making payments anywhere in the world by introducing the following: Username-based addresses vs. highly complex addresses of Bitcoin and other cryptocurrencies Self-funded model to ensure continual development and outreach Transaction fees of less than 1/10th a cent Advanced governance system to give every SmartCash holder a voice SmartNodes to enable InstantPay and other future services Easy-to-use web wallet and mobile app To learn more about SmartCash's innovations, visit https://smartcash.cc/
Medibio Announces Scientific Advisory Board26.4.2018 06:00 | Pressmeddelande
Led by Board of Director Franklyn Prendergast, M.D., Ph.D. and Chief Medical Officer Archie Defillo, M.D. Key external members include Martin Chapman, M.D.; Joel Ehrenkranz, M.D.; Mark A. Frye, M.D.; Lawrence Hunter, Ph.D.; Wallace Mendelson, M.D.; Marie Casey Olseth, M.D., and Giampaolo Perna, M.D., Ph.D. SYDNEY, Australia and MINNEAPOLIS, April 25, 2018 (GLOBE NEWSWIRE) -- Medibio Limited (MEB or the Company) (ASX:MEB) (OTCQB:MDBIF), a mental health technology company confirms establishment of its Scientific Advisory Board (SAB). Scientific Advisory Board Charter/Purpose The Medibio Scientific Advisory Board is charged to advise the board of directors and executive leadership team on scientific matters involving the Company's discovery and development of programs, including major internal projects, interactions with academic and other outside research organizations, and the acquisition of technologies. The SAB will assist directors and management to stay abreast of industry and menta
Madison Realty Capital Provides $35 Million Mezzanine Loan for 611 West 56th Street Condominium Development in Hell's Kitchen26.4.2018 00:51 | Pressmeddelande
Part of Overall $155 Million Financing Package Provided by MRC and Apollo Global Management for Planned 35 Story Condo Tower at 56th Street and Eleventh Avenue First New York City Project Designed by Renowned Architect Álvaro Siza NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Madison Realty Capital (MRC) provided a $35 million mezzanine loan to co-developers Sumaida + Khurana and LENY for a new condominium tower located at 611 West 56th Street in the Hell's Kitchen neighborhood of Manhattan. The funding is part of a $155 million construction financing package for the project provided by MRC and an investment fund managed by Apollo Global Management. Located in the evolving Hudson West neighborhood, 611 West 56th Street will stand 35 stories in height, encompass 163,329 square feet and feature 83 residences, ranging from one-bedrooms to expansive penthouses. The condominium will also feature a significant amount of outdoor space, including a landscaped roof garden and sun deck, as well a
Crocus Technology Raises $35M in Financing26.4.2018 00:36 | Pressmeddelande
Final round of financing to fuel Crocus' rapidly growing TMR magnetic sensor business SANTA CLARA, Calif., April 25, 2018 (GLOBE NEWSWIRE) -- Crocus Technology, a leading supplier of disruptive Tunnel Magneto-Resistance (TMR) sensors, today announces it has secured $35M in funding through a combination of debt and equity from internal investors and external sources. The funding will enable Crocus Technology to accelerate its revenue growth by expanding its operations and go-to-market resources and by investing in the continuous development of innovative products to serve the demand of existing and emerging markets. Crocus' proprietary MLU(TM) technology enables its TMR sensor products to have high magnetic sensitivity with minimal variation over a wide temperature range, coupled with ultra-low power consumption, which makes them ideal sensing solutions for IoT, mobile, automotive, medical and industrial applications. Crocus' TMR integrated sensor products are embedded within a CMOS pro
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum